Chronic kidney illness (CKD) is amongst the most prevalent and dire problems of diabetes mellitus in adults throughout the world. Diabetes considerably contributes to the burden of kidney illness, such that one third to at least one half of CKD in the United States and many different international locations is attributable to diabetic kidney illness (DKD). As DKD progresses to end-stage renal illness (ESRD), sufferers are at heightened danger for atypical glycemic problems, together with the improvement of burnt-out diabetes, manifested by hypoglycemic bouts and poor outcomes.
Furthermore, even in the absence of diabetes, hypoglycemia is a frequent incidence in CKD sufferers which will contribute to their excessive burden of heart problems and demise. Extrapolation of knowledge from scientific trials in high-cardiovascular-risk populations and observational research in sufferers with non-dialysis-dependent (NDD) CKD and ESRD recommend that reasonable glycemic targets outlined by glycated hemoglobin ranges of 6% to eight% and glucose ranges of 100 to 150 mg/dL are related to higher survival in DKD sufferers.
However, given the imprecision of glycated hemoglobin ranges in kidney illness, additional analysis is required to find out the optimum glycemic metric and goal in diabetic NDD-CKD and ESRD sufferers. Given their exceedingly excessive cardiovascular morbidity and mortality, there’s a compelling want for additional investigation of the way to optimally handle dysglycemia in the NDD-CKD and ESRD populations.
Dendritic Integration Dysfunction in Neurodevelopmental Disorders
Neurodevelopmental issues (NDDs) that have an effect on cognition, social interplay, and studying, together with autism spectrum dysfunction (ASD) and mental incapacity (ID), have a powerful genetic element. Our present understanding of danger genes highlights two most important teams of dysfunction: these in genes that act as chromatin modifiers and these in genes that encode for proteins localized at or close to synapses. Understanding how dysfunction in these genes contributes to phenotypes noticed in ASD and ID stays a serious query in neuroscience.
In this overview, we spotlight rising proof suggesting that dysfunction in dendrites – areas of neurons that obtain synaptic enter – could also be key to understanding options of neuronal processing affected in these issues. Dendritic integration performs a basic function in sensory processing, cognition, and acutely aware notion, processes hypothesized to be impaired in NDDs. Many high-confidence ASD genes perform inside dendrites the place they management synaptic integration and dendritic excitability.
Further, growing proof demonstrates that a number of ASD/ID genes, together with chromatin modifiers and transcription components, regulate the expression or scaffolding of dendritic ion channels, receptors, and synaptic proteins. Therefore, we talk about how dysfunction of subsets of NDD-associated genes in dendrites results in defects in dendritic integration and excitability and could also be one core phenotype in ASD and ID.
In vitro dissolution concerns related to nano drug supply techniques
Nano drug supply techniques (NDDS) supply promising answer for the translation of future nanomedicines. As bioavailability and therapeutic outcomes may be improved by altering the drug launch from these NDDS, it turns into important to completely perceive their drug launch kinetics. Moreover, U.S. Food and Drug Administration requires essential analysis of potential security, efficacy, and public well being impacts of nanomaterials. Spiraling up market share of NDDS has additionally stimulated the pharmaceutical trade to develop their cost-effective generic variations after the expiry of patent and related exclusivity.
However, in contrast to the standard dosage types, the in vivo disposition of NDDS is very intricate and totally different from their in vitro habits. Significant challenges exist in the institution of in vitro-in vivo correlation (IVIVC) attributable to incomplete understanding of nanoparticles’ in vivo biofate and its influence on in vitro experimental protocols. A rational design of dissolution might function high quality and amount management instrument and assist develop a significant IVIVC for favorable financial implications. Clinically related drug product specs (essential high quality attributes) may be recognized by establishing a hyperlink between in vitro efficiency and in vivo publicity.
In vitro dissolution can also play a pivotal function to know the dissolution-mediated clearance and security of NDDS. Prevalent in vitro dissolution strategies for NDDS and their limitations are mentioned in this overview, amongst which USP four is gaining extra curiosity lately. Researchers are working diligently to develop biorelevant in vitro launch assays to make sure optimum therapeutic efficiency of generic variations of those NDDS. This article focuses on these research and presents vital concerns for the future improvement of clinically related in vitro launch strategies.
A overview of the proof on the danger of congenital malformations and neurodevelopmental issues in affiliation with antiseizure medicines throughout being pregnant
IntroductionThe majority of ladies with epilepsy require remedy with antiseizure medicines (ASM) all through being pregnant. However, in utero publicity to a number of ASM has been related to an elevated danger of congenital malformations and/or neurodevelopmental issues (CM/NDD) in the baby, however observational proof is methodologically heterogeneous.Areas coatedWe critically consider present proof on the danger of CM/NDD in youngsters of ladies with epilepsy after in utero publicity to totally different ASM.
We spotlight traits of various information sources and talk about their advantages and drawbacks. This overview consists of proof revealed earlier than December 2020 (non-systematic literature search).Expert opinionGiven the lack of randomized managed trials, proof on in utero security of ASM originates from methodologically heterogeneous post-marketing observational research primarily based on registries, potential cohorts, and giant digital well being databases.
Dbndd1 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL504707 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Dbndd2 - Rat, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL703783 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Dbndd2 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL502919 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
DBNDD2 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL305099 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Dbndd1 ORF Vector (Rat) (pORF) |
|||
| ORF065791 | ABM | 1.0 ug DNA | 607.2 EUR |
DBNDD1 ORF Vector (Human) (pORF) |
|||
| ORF018059 | ABM | 1.0 ug DNA | 486 EUR |
Dbndd1 ORF Vector (Mouse) (pORF) |
|||
| ORF042642 | ABM | 1.0 ug DNA | 607.2 EUR |
Dbndd1 ORF Vector (Mouse) (pORF) |
|||
| ORF042643 | ABM | 1.0 ug DNA | 607.2 EUR |
Dbndd1 ORF Vector (Mouse) (pORF) |
|||
| ORF042644 | ABM | 1.0 ug DNA | 607.2 EUR |
DBNDD1 Protein Vector (Rat) (pPM-C-HA) |
|||
| PV263164 | ABM | 500 ng | 723.6 EUR |
DBNDD1 Protein Vector (Rat) (pPB-C-His) |
|||
| PV263162 | ABM | 500 ng | 723.6 EUR |
DBNDD1 Protein Vector (Rat) (pPB-N-His) |
|||
| PV263163 | ABM | 500 ng | 723.6 EUR |
DBNDD1 Protein Vector (Rat) (pPM-C-His) |
|||
| PV263165 | ABM | 500 ng | 723.6 EUR |
DBNDD1 Protein Vector (Mouse) (pPM-C-HA) |
|||
| PV170568 | ABM | 500 ng | 723.6 EUR |
DBNDD1 Protein Vector (Mouse) (pPM-C-HA) |
|||
| PV170572 | ABM | 500 ng | 723.6 EUR |
DBNDD1 Protein Vector (Mouse) (pPM-C-HA) |
|||
| PV170576 | ABM | 500 ng | 723.6 EUR |
DBNDD1 Protein Vector (Human) (pPM-C-HA) |
|||
| PV072235 | ABM | 500 ng | 662.4 EUR |
DBNDD1 Protein Vector (Mouse) (pPB-C-His) |
|||
| PV170566 | ABM | 500 ng | 723.6 EUR |
DBNDD1 Protein Vector (Mouse) (pPB-N-His) |
|||
| PV170567 | ABM | 500 ng | 723.6 EUR |
DBNDD1 Protein Vector (Mouse) (pPM-C-His) |
|||
| PV170569 | ABM | 500 ng | 723.6 EUR |
DBNDD1 Protein Vector (Mouse) (pPB-C-His) |
|||
| PV170570 | ABM | 500 ng | 723.6 EUR |
DBNDD1 Protein Vector (Mouse) (pPB-N-His) |
|||
| PV170571 | ABM | 500 ng | 723.6 EUR |
DBNDD1 Protein Vector (Mouse) (pPM-C-His) |
|||
| PV170573 | ABM | 500 ng | 723.6 EUR |
DBNDD1 Protein Vector (Mouse) (pPB-C-His) |
|||
| PV170574 | ABM | 500 ng | 723.6 EUR |
DBNDD1 Protein Vector (Mouse) (pPB-N-His) |
|||
| PV170575 | ABM | 500 ng | 723.6 EUR |
DBNDD1 Protein Vector (Mouse) (pPM-C-His) |
|||
| PV170577 | ABM | 500 ng | 723.6 EUR |
DBNDD1 Protein Vector (Human) (pPB-C-His) |
|||
| PV072233 | ABM | 500 ng | 662.4 EUR |
DBNDD1 Protein Vector (Human) (pPB-N-His) |
|||
| PV072234 | ABM | 500 ng | 662.4 EUR |
DBNDD1 Protein Vector (Human) (pPM-C-His) |
|||
| PV072236 | ABM | 500 ng | 662.4 EUR |
Dbndd1 - Rat shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml. |
|||
| TL702279V | Origene Technologies GmbH | 500 ul each | Ask for price |
DBNDD1 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml. |
|||
| TL317446V | Origene Technologies GmbH | 500 ul each | Ask for price |
Dbndd1 - Mouse shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml. |
|||
| TL504707V | Origene Technologies GmbH | 500 ul each | Ask for price |
Dbndd1/ Rat Dbndd1 ELISA Kit |
|||
| ELI-46842r | Lifescience Market | 96 Tests | 1063.2 EUR |
DBNDD1 |
|||
| pro-1162 | ProSpec Tany | 5µg | 60 EUR |
|
Description: Recombinant Human Dysbindin (Dystrobrevin Binding Protein 1) Domain Containing 1 |
|||
Dbndd1 sgRNA CRISPR Lentivector set (Rat) |
|||
| K6273401 | ABM | 3 x 1.0 ug | 406.8 EUR |
DBNDD1 sgRNA CRISPR Lentivector set (Human) |
|||
| K0563301 | ABM | 3 x 1.0 ug | 406.8 EUR |
Dbndd1 sgRNA CRISPR Lentivector set (Mouse) |
|||
| K3858501 | ABM | 3 x 1.0 ug | 406.8 EUR |
Dbndd1 sgRNA CRISPR Lentivector (Rat) (Target 1) |
|||
| K6273402 | ABM | 1.0 ug DNA | 184.8 EUR |
Dbndd1 sgRNA CRISPR Lentivector (Rat) (Target 2) |
|||
| K6273403 | ABM | 1.0 ug DNA | 184.8 EUR |
Dbndd1 sgRNA CRISPR Lentivector (Rat) (Target 3) |
|||
| K6273404 | ABM | 1.0 ug DNA | 184.8 EUR |
Dbndd1 - Rat, 4 unique 29mer shRNA constructs in retroviral untagged vector |
|||
| TR702279 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
DBNDD1 sgRNA CRISPR Lentivector (Human) (Target 1) |
|||
| K0563302 | ABM | 1.0 ug DNA | 184.8 EUR |
DBNDD1 sgRNA CRISPR Lentivector (Human) (Target 2) |
|||
| K0563303 | ABM | 1.0 ug DNA | 184.8 EUR |
DBNDD1 sgRNA CRISPR Lentivector (Human) (Target 3) |
|||
| K0563304 | ABM | 1.0 ug DNA | 184.8 EUR |
Dbndd1 sgRNA CRISPR Lentivector (Mouse) (Target 1) |
|||
| K3858502 | ABM | 1.0 ug DNA | 184.8 EUR |
Dbndd1 sgRNA CRISPR Lentivector (Mouse) (Target 2) |
|||
| K3858503 | ABM | 1.0 ug DNA | 184.8 EUR |
Dbndd1 sgRNA CRISPR Lentivector (Mouse) (Target 3) |
|||
| K3858504 | ABM | 1.0 ug DNA | 184.8 EUR |
Dbndd1 - Mouse, 4 unique 29mer shRNA constructs in retroviral untagged vector |
|||
| TR504707 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
DBNDD1 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector |
|||
| TR317446 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
DBNDD1 Protein |
|||
| abx260921-10g | Abbexa | 10 µg | 325 EUR |
DBNDD1 Protein |
|||
| 20-abx260921 | Abbexa |
|
|
DBNDD1 Protein |
|||
| abx260921-2g | Abbexa | 2 µg | 225 EUR |
Rat DBNDD1 siRNA |
|||
| 20-abx913603 | Abbexa |
|
|
DBNDD1 siRNA (Rat) |
|||
| MBS8220215-15nmol | MyBiosource | 15nmol | 405 EUR |
DBNDD1 siRNA (Rat) |
|||
| MBS8220215-30nmol | MyBiosource | 30nmol | 565 EUR |
DBNDD1 siRNA (Rat) |
|||
| MBS8220215-5x30nmol | MyBiosource | 5x30nmol | 2450 EUR |
Mouse DBNDD1 siRNA |
|||
| 20-abx913604 | Abbexa |
|
|
Human DBNDD1 siRNA |
|||
| 20-abx901417 | Abbexa |
|
|
DBNDD1 siRNA (Human) |
|||
| MBS8232890-15nmol | MyBiosource | 15nmol | 405 EUR |
DBNDD1 siRNA (Human) |
|||
| MBS8232890-30nmol | MyBiosource | 30nmol | 565 EUR |
DBNDD1 siRNA (Human) |
|||
| MBS8232890-5x30nmol | MyBiosource | 5x30nmol | 2450 EUR |
DBNDD1 siRNA (Mouse) |
|||
| MBS8231446-15nmol | MyBiosource | 15nmol | 405 EUR |
DBNDD1 siRNA (Mouse) |
|||
| MBS8231446-30nmol | MyBiosource | 30nmol | 565 EUR |
DBNDD1 siRNA (Mouse) |
|||
| MBS8231446-5x30nmol | MyBiosource | 5x30nmol | 2450 EUR |
Human DBNDD1 Antibody |
|||
| 33409-05111 | AssayPro | 150 ug | 215 EUR |
Dbndd1 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Rat) |
|||
| K6273405 | ABM | 3 x 1.0 ug | 451.2 EUR |
Recombinant Human DBNDD1 |
|||
| MBS7611380-005mg | MyBiosource | 0.05mg | 345 EUR |
Recombinant Human DBNDD1 |
|||
| MBS7611380-02mg | MyBiosource | 0.2mg | 635 EUR |
Recombinant Human DBNDD1 |
|||
| MBS7611380-1mg | MyBiosource | 1mg | 1800 EUR |
Recombinant Human DBNDD1 |
|||
| MBS7611380-5x1mg | MyBiosource | 5x1mg | 6955 EUR |
DBNDD1 Polyclonal Antibody |
|||
| MBS9235031-01mL | MyBiosource | 0.1mL | 415 EUR |
DBNDD1 Polyclonal Antibody |
|||
| MBS9235031-5x01mL | MyBiosource | 5x0.1mL | 1841 EUR |
DBNDD1 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human) |
|||
| K0563305 | ABM | 3 x 1.0 ug | 451.2 EUR |
Dbndd1 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse) |
|||
| K3858505 | ABM | 3 x 1.0 ug | 451.2 EUR |
DBNDD1 protein (His tag) |
|||
| 80R-2386 | Fitzgerald | 100 ug | 329 EUR |
|
Description: Purified recombinant Human DBNDD1 protein (His tag) |
|||
Lenti ORF clone of Dbndd1 (mGFP-tagged ORF) - Rat dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1), (10 ug) |
|||
| RR206226L4 | Origene Technologies GmbH | 10 µg | Ask for price |
Dbndd1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 1) |
|||
| K6273406 | ABM | 1.0 ug DNA | 200.4 EUR |
Dbndd1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 2) |
|||
| K6273407 | ABM | 1.0 ug DNA | 200.4 EUR |
Dbndd1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 3) |
|||
| K6273408 | ABM | 1.0 ug DNA | 200.4 EUR |
Rat DBNDD1 shRNA Plasmid |
|||
| 20-abx990198 | Abbexa |
|
|
Dbndd2 - Rat shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml. |
|||
| TL703783V | Origene Technologies GmbH | 500 ul each | Ask for price |
Mouse DBNDD1 shRNA Plasmid |
|||
| 20-abx977710 | Abbexa |
|
|
Human DBNDD1 shRNA Plasmid |
|||
| 20-abx962250 | Abbexa |
|
|
DBNDD1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1) |
|||
| K0563306 | ABM | 1.0 ug DNA | 200.4 EUR |
DBNDD1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2) |
|||
| K0563307 | ABM | 1.0 ug DNA | 200.4 EUR |
DBNDD1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3) |
|||
| K0563308 | ABM | 1.0 ug DNA | 200.4 EUR |
Dbndd1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 1) |
|||
| K3858506 | ABM | 1.0 ug DNA | 200.4 EUR |
Dbndd1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 2) |
|||
| K3858507 | ABM | 1.0 ug DNA | 200.4 EUR |
Dbndd1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 3) |
|||
| K3858508 | ABM | 1.0 ug DNA | 200.4 EUR |
Lenti ORF particles, Dbndd1 (GFP-tagged ORF) - Rat dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1), 200ul, >10^7 TU/mL |
|||
| RR206226L4V | Origene Technologies GmbH | 200 µl | Ask for price |
Lenti ORF clone of Dbndd1 (Myc-DDK-tagged ORF) - Rat dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1), (10 ug) |
|||
| RR206226L3 | Origene Technologies GmbH | 10 µg | Ask for price |
Human DBNDD1 Protein Lysate |
|||
| MBS8410297-002mg | MyBiosource | 0.02mg | 365 EUR |
Human DBNDD1 Protein Lysate |
|||
| MBS8410297-5x002mg | MyBiosource | 5x0.02mg | 1410 EUR |
DBNDD1 (NM_024043) Human Recombinant Protein |
|||
| E45H41704M5 | EnoGene | 20 ug | 785.42 EUR |
Dbndd1 (NM_028146) Mouse Recombinant Protein |
|||
| E45M44243M5 | EnoGene | 20 ug | 1924.54 EUR |
DBNDD1 (NM_024043) Human Recombinant Protein |
|||
| PROTQ9H9R9 | BosterBio | Regular: 20ug | 1249 EUR |
|
Description: Recombinant protein of human dysbindin (dystrobrevin binding protein 1) domain containing 1 (DBNDD1), transcript variant 2 |
|||
DBNDD1 Recombinant Protein (Rat) |
|||
| RP197369 | ABM | 100 ug | Ask for price |
Lenti ORF particles, DBNDD1 (Myc-DDK tagged) - Human dysbindin (dystrobrevin binding protein 1) domain containing 1 (DBNDD1), transcript variant |
|||
| RC200971L3V | Origene Technologies GmbH | 200 µl | Ask for price |
Lenti ORF particles, DBNDD1 (mGFP-tagged) - Human dysbindin (dystrobrevin binding protein 1) domain containing 1 (DBNDD1), transcript variant 2, |
|||
| RC200971L4V | Origene Technologies GmbH | 200 µl | Ask for price |
Lenti ORF particles, DBNDD1 (Myc-DDK tagged) - Human dysbindin (dystrobrevin binding protein 1) domain containing 1 (DBNDD1), transcript variant |
|||
| RC212789L3V | Origene Technologies GmbH | 200 µl | Ask for price |
Lenti ORF particles, DBNDD1 (mGFP-tagged) - Human dysbindin (dystrobrevin binding protein 1) domain containing 1 (DBNDD1), transcript variant 1, |
|||
| RC212789L4V | Origene Technologies GmbH | 200 µl | Ask for price |
Dbndd2 - Mouse shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml. |
|||
| TL502919V | Origene Technologies GmbH | 500 ul each | Ask for price |
DBNDD2 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml. |
|||
| TL305099V | Origene Technologies GmbH | 500 ul each | Ask for price |
Lenti ORF clone of Dbndd1 (mGFP-tagged) - Mouse dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1), transcript variant 3 |
|||
| MR217937L4 | Origene Technologies GmbH | 10 µg | Ask for price |
Lenti ORF clone of Dbndd1 (mGFP-tagged) - Mouse dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1), transcript variant 1 |
|||
| MR216430L4 | Origene Technologies GmbH | 10 µg | Ask for price |
Lenti ORF clone of Dbndd1 (mGFP-tagged) - Mouse dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1), transcript variant 2 |
|||
| MR216440L4 | Origene Technologies GmbH | 10 µg | Ask for price |
Lenti ORF particles, Dbndd1 (Myc-DDK-tagged ORF) - Rat dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1), 200ul, >10^7 TU/m |
|||
| RR206226L3V | Origene Technologies GmbH | 200 µl | Ask for price |
DBNDD1 Recombinant Protein (Mouse) |
|||
| RP127922 | ABM | 100 ug | Ask for price |
DBNDD1 Recombinant Protein (Mouse) |
|||
| RP127925 | ABM | 100 ug | Ask for price |
DBNDD1 Recombinant Protein (Mouse) |
|||
| RP127928 | ABM | 100 ug | Ask for price |
DBNDD1 Recombinant Protein (Human) |
|||
| RP054174 | ABM | 100 ug | Ask for price |
Lenti ORF particles, Dbndd1 (Myc-DDK-tagged) - Mouse dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1), transcript variant |
|||
| MR217937L3V | Origene Technologies GmbH | 200 µl | Ask for price |
Lenti ORF particles, Dbndd1 (Myc-DDK-tagged) - Mouse dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1), transcript variant |
|||
| MR216430L3V | Origene Technologies GmbH | 200 µl | Ask for price |
Lenti ORF particles, Dbndd1 (Myc-DDK-tagged) - Mouse dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1), transcript variant |
|||
| MR216440L3V | Origene Technologies GmbH | 200 µl | Ask for price |
Lenti ORF particles, Dbndd1 (GFP-tagged) - Mouse dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1), transcript variant 3, 2 |
|||
| MR217937L4V | Origene Technologies GmbH | 200 µl | Ask for price |
Lenti ORF particles, Dbndd1 (GFP-tagged) - Mouse dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1), transcript variant 1, 2 |
|||
| MR216430L4V | Origene Technologies GmbH | 200 µl | Ask for price |
Lenti ORF particles, Dbndd1 (GFP-tagged) - Mouse dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1), transcript variant 2, 2 |
|||
| MR216440L4V | Origene Technologies GmbH | 200 µl | Ask for price |
Lenti ORF clone of Dbndd1 (Myc-DDK-tagged) - Mouse dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1), transcript variant 3 |
|||
| MR217937L3 | Origene Technologies GmbH | 10 µg | Ask for price |
Lenti ORF clone of Dbndd1 (Myc-DDK-tagged) - Mouse dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1), transcript variant 1 |
|||
| MR216430L3 | Origene Technologies GmbH | 10 µg | Ask for price |
Lenti ORF clone of Dbndd1 (Myc-DDK-tagged) - Mouse dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1), transcript variant 2 |
|||
| MR216440L3 | Origene Technologies GmbH | 10 µg | Ask for price |
Human DBNDD1 knockout cell line |
|||
| ABC-KH3951 | AcceGen | 1 vial | Ask for price |
|
Description: Human DBNDD1 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
DBNDD1 (NM_001042610) Human Over-expression Lysate |
|||
| E45H05103-2 | EnoGene | each | 395 EUR |
DBNDD1 (NM_024043) Human Over-expression Lysate |
|||
| E45H11874-2 | EnoGene | each | 395 EUR |
DBNDD1 (NM_001042610) Human Over-expression Lysate |
|||
| LS079007 | BosterBio | 100ug | 628 EUR |
|
Description: Transient overexpression lysate of dysbindin (dystrobrevin binding protein 1) domain containing 1 (DBNDD1), transcript variant 1 |
|||
Human DBNDD1 knockdown cell line |
|||
| ABC-KD3951 | AcceGen | 1 vial | Ask for price |
|
Description: Human DBNDD1 knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest. |
|||
Human DBNDD1 Protein Lysate 20ug |
|||
| IHUDBNDD1PLLY20UG | Innovative research | each | 213 EUR |
|
Description: Human DBNDD1 Protein Lysate 20ug |
|||
Recombinant Human DBNDD1, GST-tagged |
|||
| DBNDD1-11844H | Creative BioMart | 25ug | 255.2 EUR |
|
Description: The protein is stored in PBS buffer at -20℃. Avoid repeated freezing and thawing cycles. |
|||
Human DBNDD1 Antibody (Biotin Conjugate) |
|||
| 33409-05121 | AssayPro | 150 ug | 315 EUR |
OCOA15211-20UG - DBNDD1 Protein Lysate |
|||
| OCOA15211-20UG | Aviva Systems Biology | 20ug | 169 EUR |
OCOA08431-20UG - DBNDD1 Protein Lysate |
|||
| OCOA08431-20UG | Aviva Systems Biology | 20ug | 169 EUR |
Dbndd1 (untagged ORF) - Rat dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1), (10 ug) |
|||
| RN206226 | Origene Technologies GmbH | 10 µg | Ask for price |
DBNDD1 Over-expression Lysate Product |
|||
| GWB-7044A5 | GenWay Biotech | 0.1 mg | Ask for price |
DBNDD1, 1-158aa, Human, His tag, E Coli |
|||
| MBS204279-002mg | MyBiosource | 0.02mg | 215 EUR |
DBNDD1, 1-158aa, Human, His tag, E Coli |
|||
| MBS204279-01mg | MyBiosource | 0.1mg | 340 EUR |
DBNDD1, 1-158aa, Human, His tag, E Coli |
|||
| MBS204279-05mg | MyBiosource | 0.5mg | 765 EUR |
DBNDD1, 1-158aa, Human, His tag, E Coli |
|||
| MBS204279-5x05mg | MyBiosource | 5x0.5mg | 3195 EUR |
DBNDD1 (untagged)-Human dysbindin (dystrobrevin binding protein 1) domain containing 1 (DBNDD1), transcript variant 1 |
|||
| SC311345 | Origene Technologies GmbH | 10 µg | Ask for price |
DBNDD1 (untagged)-Human dysbindin (dystrobrevin binding protein 1) domain containing 1 (DBNDD1), transcript variant 2 |
|||
| SC321574 | Origene Technologies GmbH | 10 µg | Ask for price |
DBNDD1 (untagged) - Human dysbindin (dystrobrevin binding protein 1) domain containing 1 (DBNDD1), transcript variant 3 |
|||
| SC334042 | Origene Technologies GmbH | 10 µg | Ask for price |
DBNDD1 (untagged) - Human dysbindin (dystrobrevin binding protein 1) domain containing 1 (DBNDD1), transcript variant 4 |
|||
| SC335014 | Origene Technologies GmbH | 10 µg | Ask for price |
Dbndd1 3'UTR GFP Stable Cell Line |
|||
| TU154864 | ABM | 1.0 ml | Ask for price |
DBNDD1 3'UTR GFP Stable Cell Line |
|||
| TU055580 | ABM | 1.0 ml | 1672.8 EUR |
Dbndd1 3'UTR GFP Stable Cell Line |
|||
| TU253166 | ABM | 1.0 ml | Ask for price |
Dbndd2 ORF Vector (Rat) (pORF) |
|||
| ORF065792 | ABM | 1.0 ug DNA | 607.2 EUR |
Dbndd1 (Myc-DDK-tagged ORF) - Rat dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1), (10 ug) |
|||
| RR206226 | Origene Technologies GmbH | 10 µg | Ask for price |
DBNDD2 ORF Vector (Human) (pORF) |
|||
| ORF002929 | ABM | 1.0 ug DNA | 114 EUR |
Dbndd2 ORF Vector (Mouse) (pORF) |
|||
| ORF042645 | ABM | 1.0 ug DNA | 607.2 EUR |
Dbndd2 ORF Vector (Mouse) (pORF) |
|||
| ORF042646 | ABM | 1.0 ug DNA | 607.2 EUR |
Dbndd2 ORF Vector (Mouse) (pORF) |
|||
| ORF042647 | ABM | 1.0 ug DNA | 607.2 EUR |
Dbndd2 ORF Vector (Mouse) (pORF) |
|||
| ORF042648 | ABM | 1.0 ug DNA | 607.2 EUR |
Dbndd1 (untagged) - Mouse dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1), transcript variant 1, (10ug) |
|||
| MC211300 | Origene Technologies GmbH | 10 µg | Ask for price |
Dbndd1 (untagged) - Mouse dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1), transcript variant 2, (10ug) |
|||
| MC211301 | Origene Technologies GmbH | 10 µg | Ask for price |
Dbndd1 (untagged) - Mouse dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1), transcript variant 3, (10ug) |
|||
| MC211302 | Origene Technologies GmbH | 10 µg | Ask for price |
DBNDD1 (GFP-tagged) - Human dysbindin (dystrobrevin binding protein 1) domain containing 1 (DBNDD1), transcript variant 1 |
|||
| RG212789 | Origene Technologies GmbH | 10 µg | Ask for price |
DBNDD1 (GFP-tagged) - Human dysbindin (dystrobrevin binding protein 1) domain containing 1 (DBNDD1), transcript variant 2 |
|||
| RG200971 | Origene Technologies GmbH | 10 µg | Ask for price |
Dbndd1 3'UTR Luciferase Stable Cell Line |
|||
| TU104864 | ABM | 1.0 ml | Ask for price |
DBNDD1 3'UTR Luciferase Stable Cell Line |
|||
| TU005580 | ABM | 1.0 ml | 1672.8 EUR |
Dbndd1 3'UTR Luciferase Stable Cell Line |
|||
| TU203166 | ABM | 1.0 ml | Ask for price |
DBN1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV660313 | ABM | 1.0 ug DNA | 1626 EUR |
DBN1 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV660317 | ABM | 1.0 ug DNA | 1626 EUR |
Dbndd1 (Myc-DDK-tagged) - Mouse dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1), transcript variant 3 |
|||
| MR217937 | Origene Technologies GmbH | 10 µg | Ask for price |
Dbndd1 (Myc-DDK-tagged) - Mouse dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1), transcript variant 1 |
|||
| MR216430 | Origene Technologies GmbH | 10 µg | Ask for price |
Dbndd1 (Myc-DDK-tagged) - Mouse dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1), transcript variant 2 |
|||
| MR216440 | Origene Technologies GmbH | 10 µg | Ask for price |
Dbndd1 (GFP-tagged) - Mouse dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1) transcript variant 3, (10ug) |
|||
| MG217937 | Origene Technologies GmbH | 10 µg | Ask for price |
Dbndd1 (GFP-tagged) - Mouse dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1) transcript variant 1, (10ug) |
|||
| MG216430 | Origene Technologies GmbH | 10 µg | Ask for price |
Dbndd1 (GFP-tagged) - Mouse dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1) transcript variant 2, (10ug) |
|||
| MG216440 | Origene Technologies GmbH | 10 µg | Ask for price |
DBNDD1 (Myc-DDK-tagged)-Human dysbindin (dystrobrevin binding protein 1) domain containing 1 (DBNDD1), transcript variant 2 |
|||
| RC200971 | Origene Technologies GmbH | 10 µg | Ask for price |
DBNDD1 (myc-DDK-tagged) - Human dysbindin (dystrobrevin binding protein 1) domain containing 1 (DBNDD1), transcript variant 3 |
|||
| RC236148 | Origene Technologies GmbH | 10 µg | Ask for price |
DBNDD1 (myc-DDK-tagged) - Human dysbindin (dystrobrevin binding protein 1) domain containing 1 (DBNDD1), transcript variant 4 |
|||
| RC237120 | Origene Technologies GmbH | 10 µg | Ask for price |
DBNDD1 (Myc-DDK-tagged)-Human dysbindin (dystrobrevin binding protein 1) domain containing 1 (DBNDD1), transcript variant 1 |
|||
| RC212789 | Origene Technologies GmbH | 10 µg | Ask for price |
DBN1 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV660318 | ABM | 1.0 ug DNA | 1626 EUR |
Recombinant Human DBNDD1 Protein, His, E.coli-1mg |
|||
| QP11597-1mg | EnQuireBio | 1mg | 3308.4 EUR |
Recombinant Human DBNDD1 Protein, His, E.coli-5ug |
|||
| QP11597-5ug | EnQuireBio | 5ug | 186 EUR |
Human DBNDD1 AssayLite™ Antibody (RPE Conjugate) |
|||
| 33409-05151 | AssayPro | 150 ug | 370 EUR |
Human DBNDD1 AssayLite™ Antibody (APC Conjugate) |
|||
| 33409-05161 | AssayPro | 150 ug | 370 EUR |
Recombinant Human DBNDD1 Protein, His, E.coli-20ug |
|||
| QP11597-20ug | EnQuireBio | 20ug | 241.2 EUR |
DBNDD2 Protein Vector (Rat) (pPM-C-HA) |
|||
| PV263168 | ABM | 500 ng | 723.6 EUR |
Human DBNDD1 AssayLite™ Antibody (FITC Conjugate) |
|||
| 33409-05141 | AssayPro | 150 ug | 370 EUR |
Human DBNDD1 AssayLite™ Antibody (PerCP Conjugate) |
|||
| 33409-05171 | AssayPro | 150 ug | 410 EUR |
DBNDD2 Protein Vector (Rat) (pPB-C-His) |
|||
| PV263166 | ABM | 500 ng | 723.6 EUR |
DBNDD2 Protein Vector (Rat) (pPB-N-His) |
|||
| PV263167 | ABM | 500 ng | 723.6 EUR |
DBNDD2 Protein Vector (Rat) (pPM-C-His) |
|||
| PV263169 | ABM | 500 ng | 723.6 EUR |
DBNDD2 Protein Vector (Mouse) (pPM-C-HA) |
|||
| PV170580 | ABM | 500 ng | 723.6 EUR |
DBNDD2 Protein Vector (Mouse) (pPM-C-HA) |
|||
| PV170584 | ABM | 500 ng | 723.6 EUR |
DBNDD2 Protein Vector (Mouse) (pPM-C-HA) |
|||
| PV170588 | ABM | 500 ng | 723.6 EUR |
DBNDD2 Protein Vector (Mouse) (pPM-C-HA) |
|||
| PV170592 | ABM | 500 ng | 723.6 EUR |
DBNDD2 Protein Vector (Human) (pPM-C-HA) |
|||
| PV011715 | ABM | 500 ng | 394.8 EUR |
DBNDD2 Protein Vector (Mouse) (pPB-C-His) |
|||
| PV170578 | ABM | 500 ng | 723.6 EUR |
Is has been clearly demonstrated that valproate is related to a excessive danger of CM/NDD, whereas lamotrigine and levetiracetam are comparatively secure. However, proof is much less express for different ASM. Reported dangers differ relying on the measurement and origin of the underlying examine inhabitants, the definition of publicity and outcomes, and different features of the examine design. Increased collaboration between information sources to extend pattern measurement are fascinating.
0